H.C. Wainwright analyst Matthew Caufield raised the firm’s price target on Kodiak Sciences (KOD) to $58 from $38 and keeps a Buy rating on the shares. The firm cites the positive tarcocimab update for the target boost. The Phase 3 GLOW2 trial in diabetic retinopathypatients served to validate the reformulated tarcocimab tedromer design, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KOD:
- Kodiak Sciences price target raised to $56 from $39 at Jefferies
- Midday Fly By: Corebridge to merge with Equitable
- Video: Memory stocks slipping amid worries about Google compression technique
- Morning Movers: Kodiak Sciences skyrockets following GLOW2 study results
- Kodiak Sciences reports GLOW2 study of Zenkuda met primary endpoint